When it comes to 5G, Houston is setting itself up as a leader within the United States. Getty Images

Last year, Houstonians Clayton and Emily Harris became the first commercial 5G customers. Now, a full year later, the Houston has a major seat at the table that's discussing the advancement of 5G technology.

At a forum on Tuesday, October 1, hosted by CTIA and the Center for Houston's Future, experts discussed Houston's role in the conversation about 5G. Here are some overheards from the morning event.

“We cannot take our leadership in 4G for granted as we transition to 5G.”

— Senator Ted Cruz. Cruz's keynote address warns of the United States resting on its laurels in the race to 5G. While the country had the edge on foreign competition for 4G, that doesn't mean 5G will have the same result, he says. In fact, Cruz cites multiple studies that show China and South Korea lead the race in 5G. Deloitte's research found that China has outspent the U.S. by $24 billion and has built 350,000 new sites, while the U.S. has built fewer than 30,000. The study also showed China is prepared to invest $400 billion. This information aside, Cruz tells the crowd that America has the ability to win the race to 5G.

“I think it’s a wonderful story to see how Texas has been leading the way.” 

— Brendan Carr, FCC commissioner. Carr references the Harris family, as well as other Texas cities he's visited that have been working hard to advance 5G. For Carr, expanding and implementing 5G is a huge opportunity for job creation. "The U.S. isn't the only country in the world that wants these jobs," he says to the crowd. "They're not the only country that wants to see the half a trillion dollars in economic growth that's going to come from this next-generation technology."

“I’ll admit, I’m an optimist, but there are significant challenges to making this 5G future a reality.”

— Jesse Bounds, director of innovation for the city of Houston. Bounds cited a few obstacles to overcome. There's a need for massive investment in infrastructure to blanket cities in 5G, and telecom companies are expected to spend $8 billion over the next five years to build this infrastructure, and cities too will need to invest in smart city technology. Consumers will need to pay more for data, and US consumers pay some of the highest rates in the world already. Not to mention the fact that a third of Americans don't have access to home internet. "As we build the infrastructure of the future, we must do so in a way that closes the digital divide so that those Americans can enjoy the same level of opportunity and prosperity that we do," Bounds says.

"Houston’s 5G network performance is 17 times better than the 4G. That’s today, in the very early days of 5G.”

— Paul Challoner, vice president of network product solutions at Ericsson. Challoner tells the crowd that of course this affects speed of data transferring and that is a huge pro for the technology, but there are other important perks for 5G advancement. The tech also affects device density, meaning that, a very large city like Houston, might have issues in dense areas. 5G also improves connectivity in crucial situations, like in the case of a surgeon using a device during surgery. Lastly, Challoner mentioned 5G is the most advanced technology when it comes to cybersecurity.

"One area that I’m most excited about is all the things that we don't talk about. All the applications that haven't yet been imagined, that are being dreamt up by software developers in their dorm rooms."

— Mishka Dehghan, vice president of 5G development at Sprint. Dehghan points out that 10 years ago, no one could have imagined ride sharing, now that is a huge industry with developing technology thanks to mobile data usage. With with the onset of 5G, she says she can't wait to see what technology is created in the next 10 years.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”